The global hemostats market size was valued at USD 2.95 billion in 2025 and is projected to grow from USD 3.13 billion in 2026 to  USD 4.98 billion by 2034 at a CAGR of 5.99% during the forecast period 2026–2034. North America dominated the hemostats market with a market share of 38.2% in 2025.
The Hemostats Market refers to the industry focused on the development, manufacturing, and distribution of products used to control bleeding during surgical procedures, trauma care, and emergency treatment. Hemostatic products include mechanical, active, flowable, and sealant-based agents that promote rapid blood clotting.
Download a Free Sample To learn more about this report,
The Hemostats Market trends are being driven by the increasing number of surgical procedures and the growing demand for products that can quickly control bleeding and reduce complications. Hospitals are increasingly adopting advanced absorbable hemostatic agents made from gelatin, oxidized regenerated cellulose, collagen, and thrombin because they improve surgical efficiency and minimize blood loss. These products are widely used in cardiovascular, orthopedic, neurological, and general surgeries, where rapid bleeding control is essential. The trend toward minimally invasive procedures is also encouraging the development of easy-to-apply hemostatic products compatible with laparoscopic and robotic surgeries.
Another important Hemostats Market trend is the increasing development of bioactive and regenerative hemostatic materials that not only stop bleeding but also support wound healing. Manufacturers are investing in synthetic and biologically derived hemostats with improved biocompatibility, reduced infection risk, and faster tissue recovery. Healthcare providers are also adopting combination products that integrate sealing and hemostatic functions to improve surgical outcomes.
The hemostats market is primarily driven by the increasing number of surgical procedures, rising prevalence of trauma injuries, and growing demand for effective blood loss management. Hospitals are increasingly adopting advanced hemostatic agents to reduce surgical complications and improve patient recovery. The expansion of minimally invasive and cardiovascular surgeries is further supporting product demand.
The hemostats market is restrained by the high cost of advanced products and limited affordability in developing healthcare systems. Premium biologic and combination hemostats often carry significantly higher prices than conventional bleeding control products, limiting widespread adoption in cost-sensitive hospitals.
The hemostats market offers significant opportunities through the development of next-generation bioactive and synthetic hemostatic products. Growing adoption of robotic-assisted surgery, increasing healthcare investments in emerging economies, and rising demand for outpatient surgical procedures are creating new growth avenues.
The hemostats market faces challenges related to maintaining product safety, meeting stringent regulatory standards, and managing complex manufacturing processes. Manufacturers must demonstrate consistent clinical performance while complying with evolving quality and sterilization requirements across multiple regulatory jurisdictions.
Request Customizationto receive a tailored report.
Thrombin Based Hemostats Dominated the Market with 34.6% Share in 2025
The thrombin based hemostats segment accounted for the largest share of the global hemostats market at 34.6% in 2025, generating USD 1.02 billion in revenue. The segment dominates due to its rapid clot formation, high effectiveness in controlling surgical bleeding, and widespread use across orthopedic, cardiovascular, and general surgical procedures.
Powder Hemostats are Projected to Register the Fastest Growth at a CAGR of 8.3%
The powder hemostats segment is projected to grow at the fastest rate, registering a CAGR of 8.3% during the forecast period. Increasing adoption in trauma care, emergency medicine, and difficult-to-access bleeding sites is accelerating demand for powder-based hemostatic products.
Orthopedic Surgery Dominated the Market with 23.8% Share in 2025
The orthopedic surgery segment accounted for the largest share of the global hemostats market at 23.8% in 2025, generating USD 0.70 billion in revenue. Rising numbers of joint replacement procedures, fracture treatments, and sports injury surgeries are driving strong demand for advanced hemostatic products in orthopedic applications.
Ambulatory Surgical Centers are Projected to Register the Fastest Growth at a CAGR of 8.0%
The ambulatory surgical centers segment is expected to register the fastest growth, with a CAGR of 8.0% during the forecast period. Increasing preference for outpatient surgeries, lower treatment costs, shorter hospital stays, and growing investments in ambulatory care infrastructure are driving demand for hemostatic products in these facilities.
Speak to an Analystto discuss market opportunities.
North America accounted for 38.2% of the global hemostats market, valued at USD 1.13 billion in 2025. The region benefits from advanced healthcare infrastructure, a high volume of surgical procedures, strong adoption of minimally invasive surgeries, and increasing demand for advanced hemostatic products. Favorable reimbursement policies and continuous investments in surgical technologies continue to support market expansion. The region is projected to grow at a CAGR of 6.1% during the forecast period.
The United States accounted for an estimated USD 0.97 billion in 2025, making it the largest contributor in North America. Growth is driven by increasing orthopedic, cardiovascular, and neurological surgeries, rising trauma cases, and widespread adoption of advanced thrombin-based and combination hemostatic products across hospitals and ambulatory surgical centers.
Canada generated an estimated USD 0.16 billion in 2025. Rising healthcare expenditure, increasing surgical volumes, expanding adoption of minimally invasive procedures, and growing investments in modern hospital infrastructure are driving demand for hemostatic products across the country.
Europe accounted for 27.4% of the global hemostats market, reaching USD 0.81 billion in 2025. The market is supported by well-established healthcare systems, increasing numbers of complex surgical procedures, expanding elderly populations, and growing adoption of advanced surgical hemostatic technologies. The region is expected to register a CAGR of 6.3% during the forecast period.
The United Kingdom represented an estimated USD 0.15 billion in 2025. The country's market is driven by increasing NHS investments in surgical care, rising demand for advanced bleeding management products, and growing adoption of minimally invasive surgical techniques.
Germany accounted for an estimated USD 0.21 billion in 2025, making it one of Europe's leading hemostats markets. Strong healthcare infrastructure, high surgical procedure volumes, and continuous investments in innovative surgical technologies continue to support market growth.
Asia Pacific accounted for 22.1% of the global hemostats market, valued at USD 0.65 billion in 2025, and is projected to register the fastest regional CAGR of 8.4% during the forecast period. Rising healthcare expenditure, expanding hospital infrastructure, increasing surgical procedures, and growing awareness of advanced bleeding control products are accelerating market growth across the region.
Japan generated an estimated USD 0.14 billion in 2025. The country's aging population, increasing demand for orthopedic and cardiovascular surgeries, and widespread use of advanced surgical technologies continue to fuel demand for hemostatic products.
China accounted for an estimated USD 0.27 billion in 2025, making it the largest market in Asia Pacific. Rapid healthcare infrastructure development, rising surgical volumes, increasing government healthcare investments, and growing domestic production of surgical products are driving strong market growth.
The Middle East & Africa represented 5.2% of the global hemostats market, totaling USD 0.15 billion in 2025. Increasing healthcare investments, improving access to advanced surgical care, rising trauma cases, and expanding hospital infrastructure are supporting regional market growth. The market is projected to grow at a CAGR of 6.6% during the forecast period.
The United Arab Emirates (UAE) accounted for an estimated USD 0.04 billion in 2025. The market is driven by investments in healthcare modernization, increasing surgical procedures, growing medical tourism, and rising adoption of advanced surgical consumables in public and private hospitals.
Africa is witnessing steady growth in the hemostats market, supported by expanding healthcare infrastructure, increasing access to surgical services, and rising government investments in trauma and emergency care. In 2025, the regional African market was estimated at USD 0.11 billion. Growing demand for safe and effective bleeding control products, along with improving surgical capabilities across major economies, is expected to create long-term growth opportunities.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Jay Mehta is a Research Analyst with over 4 years of experience in the Medical Devices industry. His expertise spans market sizing, technology assessment, and competitive analysis. Jay’s research supports manufacturers, investors, and healthcare providers in understanding device innovations, regulatory landscapes, and emerging market opportunities worldwide.
We are featured on:
sales@straitsresearch.com